Tacrolimus could suppress PVR development

Article

Application of intravitreal tacrolimus could suppress the development of proliferative vitreoretinopathy (PVR).

Application of intravitreal tacrolimus could suppress the development of proliferative vitreoretinopathy (PVR), reveals a paper in Retina.

The investigation, led by Dr Burak Turgut, Department of Ophthalmology, Firat University School of Medicine, Elazig, Turkey, consisted of 21 guinea pigs randomly and evenly assigned to three groups. The groups included a non-PVR group injected with saline, a dispase-induced PVR group injected with saline and a dispase-induced PVR group injected with tacrolimus.

Eyes were enucleated after the investigation and the stages of PVR were identified. Halves of the enucleated globes were histopathologically evaluated for PVR formation and the retinas of the other halves of globes were used to prepare retinal homogenates. The enzyme-linked immunsorbent assay method was used to measure transforming growth factor-β, platelet-derived growth factor, and fibroblast growth factor levels in homogenized retina tissues.

The average PVR stages in the tacrolimus group significantly improved compared to the PVR-saline group. The tacrolimus group also presented with lower levels of transforming growth factor-β, platelet-derived growth factor and fibroblast growth factor. Significant improvement was identified in epiretinal membrane formation and retinal fold in the tacrolimus group.

The study implies that tacrolimus could be helpful towards investigating the prophylaxis of PVR.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.